Articles tagged with Targeted Drug Delivery
Researchers identify CLASS 3G subtype of EGFR mutation associated with limited response to targeted drugs. This structural subtype alters protein shape, reducing treatment efficacy and allowing for more effective combination therapy.
Researchers have developed molecular cages that encase tetrazine, allowing for specific targeting of cancer cells for imaging and drug delivery. This technology enables precise spatial control over chemical reactions in living systems, promising improved outcomes for patients with limited side effects.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
Researchers Dr Íris Luz Batalha and Dr Maria Shchepinova from the University of Bath have been awarded funding to test new ideas in tackling global health challenges. They will develop precision-targeted therapies for antimicrobial resistance and investigate why treatments for Type 2 diabetes don't work for everyone.
Researchers developed a nasal spray that reversibly reduces brain inflammation, restores cellular power plants, and improves memory. The treatment bypasses the brain's protective shield through intranasal delivery, suppressing chronic inflammation and promoting successful brain aging.
Researchers at VCU Massey Comprehensive Cancer Center developed a targeted therapy that effectively prevents prostate tumors from spreading to the bone. The small molecule inhibitor IVMT-Rx-4 blocks the function of MDA-9/Syntenin, preventing tumor growth and improving survival in models with bone metastasis.
Researchers at Aarhus University have developed an artificial virus-like DNA needle that can deliver molecules directly into cells. The technique uses DNA origami to assemble the needle and deliver its payload, potentially solving a major issue with many therapies being trapped inside cells.
A new system generates oxygen, sustaining drug-producing cells for weeks. The device, called HOBIT, integrates engineered cells with oxygen-producing bioelectronics, producing three different biologics in a small animal model.
A new RNA therapy has been developed to enhance the heart's own ability to protect and repair itself after a heart attack. The therapy, which involves injecting particles into the arm, significantly reduced scarring and improved heart function in lab experiments, offering a potential breakthrough for heart patients.
The University of Missouri has launched its first human clinical trial using Eye90 microspheres, a radiopharmaceutical breakthrough device manufactured on campus. The study aims to assess the safety and effectiveness of Eye90 in treating unresectable liver tumors, including hepatocellular carcinoma and metastatic colorectal cancer.
Researchers have developed a long, needle-thin brain electrode with channels that enables neural signal recording and precisely targeted medication delivery across different brain regions. The technology has primarily been developed for basic research but may be important for future treatments in epilepsy and other neurological diseases.
A Purdue-developed mRNA therapy delivery system has shown promise in targeting bladder cancer cells with improved efficiency. The system, called LENN, can be freeze-dried and stored for several days without losing its biological activity.
A new patch developed by Texas A&M University researcher Dr. Ke Huang may offer a way to help the heart heal after a heart attack by delivering interleukin-4 directly to damaged heart tissue. The patch uses a microneedle system to promote repair and improve heart function without affecting the rest of the body.
A swarm of miniature magnetic soft robots, inspired by fish schools, can coordinate their movements to deliver targeted drug therapy to diseased tissue. The robots can navigate through narrow passages and adapt their shape to conform to the lesion's boundaries for optimal drug delivery coverage.
MIT engineers have developed a programmable drug-delivery patch that can reduce damaged heart tissue by 50 percent and improve cardiac function. The patch is designed to release different drugs at specific times, promoting healing and regeneration of cardiac tissue.
Scientists re-engineered a common chemotherapy drug to make it more soluble and effective, targeting cancer cells while leaving healthy tissues unharmed. The new nanomedicine significantly extended survival in animal models of leukemia, showing promise for improved cancer treatment.
Researchers designed proteins with autonomous decision-making capabilities, controlling their localization based on environmental cues. This breakthrough enables more finely targeted drug delivery, reducing off-target effects and improving therapy efficacy.
Researchers have created a new class of lipid nanoparticles (LNPs) with complex internal arrangements, expanding their potential for carrying small-molecule drugs, proteins, metal ions, and mRNA. The breakthrough offers flexibility in designing delivery systems for different therapeutic molecules.
A new biotechnical vector, VIBV, combines viral mimicry with synthetic nanotechnology to deliver targeted RNA therapies for cancer treatment. The vector uses a spindle-shaped nanostructure and polyethylene glycolylated liposomal coat to evade immunity and extend circulation.
Researchers developed pH-responsive graphene-based nanocarriers that can target cancer cells, achieving efficient and safe drug delivery. The material's surface charge adapted to the acidic tumor environment, allowing it to bind and enter cancer cells while avoiding healthy tissues.
Researchers at the University of Arkansas have created a new controlled release system that uses cellulose nanocrystals and alginate to deliver bioactive compounds to specific areas of the body. The system protects medications from acid in the stomach and releases them in alkaline environments, such as the intestines.
Researchers create microscopic drug delivery capsules with precise control over particle sizes, ideal for inhalation delivery applications. The Sequential NanoPrecipitation (SNaP) process tackles the challenge of producing uniform therapeutic particles at industrial scales.
Michael Danquah, a professor at University of Tennessee at Knoxville, has been elected Fellow of the Royal Society of Biology for his significant contributions to biotechnology and molecular bioengineering. His research in biosensing, bioremediation, and targeted drug delivery addresses critical healthcare and environmental challenges.
A novel nanocarrier system utilizing metal-polyphenols enables precise intracellular delivery of therapeutic antibodies into cancer cells. This technology overcomes endosomal entrapment, resulting in suppressed tumor growth and enhanced anti-cancer activity.
A new gene therapy delivery device called NANOSPRESSO could revolutionize how hospitals treat rare diseases by allowing them to create personalized nanomedicines in-house. This democratized approach to precision medicine could boost access to low-cost bespoke gene and RNA therapies, especially in low-resource settings.
A new approach enables hospital pharmacists to rapidly create bespoke medicine cartridges for rare disease patients, boosting access to personalized treatment. The NANOSPRESSO platform could open up treatments for underfunded and underserved rare conditions worldwide.
Researchers developed self-propelled ferroptosis nanoinducers to enhance cancer therapy by inducing programmed cell death. The nanotherapeutics exhibited enhanced diffusion and deep tumor penetration while maintaining biocompatibility.
Researchers have developed a technique for in vivo 3D printing of polymers using sound localization, which can be used for drug delivery, tissue repair, and internal wound sealing. The new method, called deep tissue in vivo sound printing (DISP), has been successfully tested in mice and shows promising results.
Researchers developed DNA origami structures that selectively deliver fluorescent imaging agents to pancreatic cancer cells, enabling more accurate cancer imaging and selective chemotherapy delivery. The study also explored the use of origami-folded DNA molecules loaded with chemotherapy drugs for targeted delivery to cancer cells.
A novel cannula delivery system allows repeated, nondisruptive delivery of imaging agents to the mouse brain during long-term multiphoton microscopy. This innovation enhances longitudinal studies on brain function, disease progression, and potential treatments.
Researchers have developed drug-delivering aptamers that target and kill leukemia stem cells, reducing the need for high doses of chemotherapy. The aptamers pair well with existing drugs like daunorubicin to deliver a targeted one-two knockout punch against cancer.
A new class of zwitterionic phospholipids, DOPE-Cx, enhances the functional delivery of mRNA via lipid nanoparticles, overcoming endosomal escape and improving mRNA expression. This breakthrough paves the way for advanced therapeutic applications, including mRNA vaccines, cancer treatment, and protein replacement therapy.
A new bacterial protein, BeeR, has been identified and its structure is being used to develop protein nanoparticles for targeted cancer drug delivery. The protein forms a hollow tube with a cavity capable of containing drug molecules.
Engineered platelets-based nano-aircraft carriers enhance targeted chemotherapy with graded drug release, promoting antitumor immune response and reducing metastasis. Researchers successfully develop Pts-based nanovesicles for precise cancer treatment.
A team of researchers from Chiba University has developed a novel radioactive drug that targets and treats metastatic melanoma. The treatment utilizes astatine-211 labeled peptide analog, which shows high accumulation in tumors, rapid clearance from non-target organs, and significant tumor suppression.
A UMass Amherst Ph.D. student has been awarded a €20,000 grant to investigate a new therapeutic target for Lyme disease by targeting the GuaB enzyme necessary for Borrelia burgdorferi replication in mammals.
Researchers have developed a palladium-mediated reaction to precisely modify peptides and proteins, overcoming challenges in bioconjugation. The method targets dehydroalanine-containing peptides and proteins, enabling efficient synthesis of structurally unique peptides.
The FDA has approved a new treatment for Parkinson's disease that can adjust to the individual's brain activity, providing precise stimulation. This technology, known as adaptive deep brain stimulation (aDBS), detects patterns of brain activity and delivers tailored electric pulses to reduce symptoms.
Ebru Demir aims to study how groups of AI-driven microswimmers move in biological fluids for potential applications in drug delivery, fertility treatments, and other medical fields. Her research combines artificial microswimmers with machine learning to uncover the underlying physics governing their movement.
Researchers at Pusan National University have developed a novel drug delivery system that uses nanoparticles to target and kill colorectal cancer cells. The system, which involves encapsulating cancer cell-activated nanoconjugates in an alginate matrix, can selectively deliver drugs to tumor cells while minimizing side effects.
Researchers discover how an anticancer drug triggers an 'outside in' signal to get sucked into a cancer cell, providing insights into adhesion regulation and potential drug design targets. The study reveals a new mechanism for delivering drugs using P-cadherin protein.
Researchers have developed a new gene therapy that targets aggressive brain cancer, glioblastoma, with a precise delivery system. The treatment uses a novel virus to deliver a targeting drug to cancer cells, achieving cure rates of up to 90% in mouse models.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
The team's novel technique enables high-throughput screening of nanoparticle shapes, sizes, and modifications, reducing associated screening costs. The research demonstrates the distinct preferences of tumour cells for certain nanoparticle configurations, enabling personalized cancer treatments that are safer and more effective.
Researchers developed ProteinReDiff, an AI-powered method to redesign proteins for improved ligand binding. The approach uses initial protein sequences and ligand SMILES strings, reducing reliance on detailed structural data.
Researchers at UMass Amherst have developed a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. The therapy uses genetically engineered strains of Salmonella that can target tumors and control the release of cancer-fighting drugs inside cancer cells.
Researchers from Trinity College Dublin have developed 'Malteser-like' molecules that can be governed to produce predictable and desirable self-assembly structures. These molecules hold promise for applications in highly sensitive sensors, next-gen targeted drug delivery agents, and luminescence-based monitoring.
Researchers have developed peptide-guided nanoparticles that can target specific cells in the brain, including neurons, marking a significant step toward potential mRNA treatments for neurological diseases. The innovation uses peptides to precisely deliver mRNA to endothelial cells lining blood vessels and neurons.
Engineered yeast cells can form cooperative groups that perform complex tasks and self-regulate in response to external signals. This approach enables precise production of therapeutic compounds, reducing waste and increasing treatment efficacy.
Researchers at the University of Illinois have created a DNA-made nanorobot called NanoGripper that can pick up COVID-19 viruses for rapid detection and block viral particles from entering cells. The device also has potential applications in cancer treatment and preventive medicine.
Vanderbilt University Medical Center is developing novel uterine-targeted delivery systems for therapeutics known as tocolytics, aiming to improve maternal and fetal safety. The project, funded by ARPA-H and DavosPharma, seeks to prolong pregnancies and allow crucial development of significant organs.
This review article investigates the druggability and molecular targets of celastrol, a natural compound for treating inflammation, cancer, and neurodegeneration. The study highlights the importance of nanoparticle-mediated delivery systems for safe and effective treatment of chronic diseases.
Researchers developed a nanomedicine that attacks bacteria at the molecular level, reducing antibiotic resistance and side effects. The technology releases medication only when required, ensuring patients take exact amounts to fight infections.
Researchers developed grain-sized soft robots that can transport up to four different drugs, release them in reprogrammable orders and doses, and navigate complex environments inside the human body. The robots' precision functions have the potential to significantly improve therapeutic outcomes while minimizing side effects.
Researchers developed a novel approach to optimizing siRNA-loaded lipid nanoparticles using NMR-based molecular-level characterization. Pre-mixed LNPs exhibit superior gene-silencing effects due to a stacked bilayer structure that enhances gene silencing.
Researchers developed a novel compound to target prostate cancer using radioactive atom astatine-211, potentially overcoming issues with previous compounds like deastatination. The study found high accumulation in tumors and low accumulation in vital organs, highlighting the potential of this new compound for targeted alpha therapy.
Researchers from HKUST developed a novel magnetic actuation platform enabling the efficient production of sperm-like micro-robots, which demonstrate excellent motility and precision in targeted drug delivery. The Vortex Turbulence-Assisted Microfluidics (VTAM) platform streamlines the production process, paving the way for promising bi...
The LENN system protects and efficiently releases NA therapies within the cytoplasm of target cells, overcoming low efficiencies and immune system clearance issues. It is biomanufacturable, biodegradable, and highly tunable, targeting a variety of cells depending on their tumor-specific surface markers.
Researchers developed tumor cell-coated carbon nanohorns to deliver paclitaxel to colon cancer, exhibiting high accumulation at tumors and strong chemotherapeutic effects. The treatment also demonstrated a robust photothermal effect and immune responses, effectively destroying tumors.
Researchers at the University of Cincinnati are developing a new technology using magnetic nanoparticles to deliver medications directly to the inner ear, where hearing loss occurs. The goal is to create an effective and minimally invasive treatment option for various types of hearing loss.